ACHV Beyond The Short Squeeze
The fact of the matter is that while the short squeeze is driving attention for Achieve Life Sciences, the company represents a strong opportunity outside of the squeeze. It has to do with smoking.
Over the past decade or so, we’ve seen a big push to get smokers to quit smoking cigarettes. However, doing so is very difficult. In order to fight the addiction, smokers spend more than $21 billion annually on products that are designed to help them quit.
With that ACHV is working on a smoking cessation product known as cytisinicline, and has had some pretty strong success. In fact, about a month ago, the company released the results from an investigator-initiated study that compared cytisinicline to the top smoking cessation drug on the market, Chantix.
Importantly, cytisinicline outperformed Chantix, setting the stage for the company to push toward commercialization with a drug that represents a multi-billion dollar opportunity.
So, even without the short squeeze, the promise offered through cytisinicline suggests that you should be paying close attention to ACHV stock.
Market Data 
Markets 
AI
